Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Restelli, Umberto; Alberti, Alfredo; LAZZARIN, ADRIANO; Bonfanti, Marzia; Nappi, Carmela; Croce, Davide

research article

oai:www.research.unipd.it:11577/3252503

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Authors: Umberto Restelli
Alfredo Alberti
ADRIANO LAZZARIN
Marzia Bonfanti
Carmela Nappi
Davide Croce
Publication date: 1 January 2016
Publisher: Springer Verlag
Doi

Abstract

Abstract is not available.

Similar works

Full text

Archivio istituzionale della ricerca - Università di Padova

oai:www.research.unipd.it:1157...

Last time updated on 17/12/2017

This paper was published in Archivio istituzionale della ricerca - Università di Padova.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.